Wyeth-Ayerst and TheraTech Collaborate to Market Testosterone Transdermal Patch

Strategic Insights -

TheraTech Inc. and Wyeth-Ayerst International Inc., a division of American Home Products Corp., have entered into an agreement to market TheraTech's testosterone transdermal patch in Mexico, Central and South America, non-French-speaking Africa, and the Middle East. The patch is intended for the treatment of male hypogonadism, a condition in which the body produces insufficient amounts of testosterone. The agreement gives Wyeth-Ayerst exclusive marketing and distribution rights in those countries, while TheraTech retains manufacturing rights and receives fees and milestone payments.

Key Takeaways:

  • The testosterone transdermal patch is designed to treat male hypogonadism, a condition affecting 4-5 million men in the United States alone.
  • The patch is intended to deliver testosterone through the skin in a manner that mimics the normal physiological pattern of testosterone production in healthy young men.
  • Wyeth-Ayerst has secured exclusive marketing and distribution rights for the patch in Mexico, Central and South America, non-French-speaking Africa, and the Middle East.
  • TheraTech has retained manufacturing rights and will receive fees and milestone payments from Wyeth-Ayerst under the agreement.
  • The patch is a patient-friendly treatment option, producing physiological hormone levels.
  • TheraTech has established marketing and distribution for its testosterone patch worldwide, except for parts of Asia.
  • TheraTech has partnered with several companies, including Procter & Gamble, Pfizer, SmithKline Beecham, Solvay Pharmaceuticals, and Syntex, for research and licensing agreements.

Statistics:

  • 4-5 million men in the United States alone suffer from testosterone deficiency.
  • The testosterone transdermal patch is designed to mimic the normal physiological pattern of testosterone production in healthy young men.
  • TheraTech patch is a patient-friendly treatment option, producing physiological hormone levels.

Sources:

  • "Wyeth-Ayerst and TheraTech Announce Agreement to Market TheraTech's Testosterone Transdermal Patch." Business Wire, October 12, 1995.
  • TheraTech Inc. press release, as reported in Business Wire, October 12, 1995.